Anti-von Willebrand Factor [RFF-VIII:R/1]
Invented by Prof Alison Goodall from University Of Leicester
Invented at University College London
- Datasheet
- References (13)
- Inventor Info
Info
| Catalogue Number | 151528 |
| Applications | ELISA FACS IF Fn RIA WB |
| Antigen/Gene or Protein Targets | Von Willebrand factor (VWF) |
| Reactivity | Primate |
| Relevance |
Anti-Anti-Von Willebrand Factor [RFF-VIII:R/1] specifically binds to human factor VIII related antigen (VIII:RAg) in plasma and in vascular endothelial cells but has no reactivity with factor VIII procoagulant antigen (VIII:cAg). This antibody is a potent inhibitor of von Willebrand factor activity in that it can totally neutralise risocetin-induced aggregation of platelet rich plasma and inhibit platelet adhesion at high flow rates. RFF-VIII:R/2 can be used in a one-stage, fluid phase immunoradiometric assay that can detect VIII:RAg. This monoclonal antibody binds to human von Willebrand factor (VW) and inhibits it's binding to platelets. Very similar in characteristics to RFF-VIII:R/1. |
| Host | Mouse |
| Immunogen | Purified human Factor VIII-VWF complex |
| Subclass | IgG1 kappa |
| Myeloma Used | P3/NS1/1-Ag4.1 |
| Recommended Growing Conditions | RPMI+10% FCS; non-adherent; subculture every 2-3 days; split 1:5 |
| Notes | IHC - Paraffin recommended dilution of 1:50 - 1:200 |
| Research Area | Cardiovascular, Stem Cell Biology |
References: 13 entries
[Use of RFF-VIII:R/1 in the purification of FVIII]
Murdock et al. 1997. Thromb Haemost. 78(4):1272-7. PMID: 9364997.
von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.
Europe PMC ID: 9364997
Takase et al. 1987. Br J Haematol. 66(4):497-502. PMID: 3117089.
Production of factor VIII deficient plasma by immunodepletion using three monoclonal antibodies.
Europe PMC ID: 3117089
McCraw et al. 1987. Thromb Res. 45(1):101-8. PMID: 3494325.
A monoclonal antibody based immunoradiometric assay for von Willebrand factor: survey of a large patient group.
Europe PMC ID: 3494325
Chand et al. 1986. Thromb Haemost. 55(3):318-24. PMID: 2428124.
A two-site, monoclonal antibody-based immunoassay for von Willebrand factor--demonstration that vWF function resides in a conformational epitope.
Europe PMC ID: 2428124
Rotblat et al. 1985. Biochemistry. 24(16):4294-300. PMID: 2413885.
Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies.
Europe PMC ID: 2413885
Goodall et al. 1985. Br J Haematol. 59(4):565-77. PMID: 2580547.
An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope.
Europe PMC ID: 2580547
Add a reference
References: 13 entries
[Use of RFF-VIII:R/1 in the purification of FVIII]
Murdock et al. 1997. Thromb Haemost. 78(4):1272-7. PMID: 9364997.
von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.
Takase et al. 1987. Br J Haematol. 66(4):497-502. PMID: 3117089.
Production of factor VIII deficient plasma by immunodepletion using three monoclonal antibodies.
McCraw et al. 1987. Thromb Res. 45(1):101-8. PMID: 3494325.
A monoclonal antibody based immunoradiometric assay for von Willebrand factor: survey of a large patient group.
Chand et al. 1986. Thromb Haemost. 55(3):318-24. PMID: 2428124.
A two-site, monoclonal antibody-based immunoassay for von Willebrand factor--demonstration that vWF function resides in a conformational epitope.
Rotblat et al. 1985. Biochemistry. 24(16):4294-300. PMID: 2413885.
Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies.
Goodall et al. 1985. Br J Haematol. 59(4):565-77. PMID: 2580547.
An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope.
Add a reference
Inventor Information
Inventors
|
Prof Alison Goodall |
